Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams | Zendy

Ian R. Reid | Zendy; Dennis M. Black | Zendy; Richard Eastell | Zendy; Christina BucciRechtweg | Zendy; Grace L. Su | Zendy; Trisha F. Hue | Zendy; Peter Mesenbrink | Zendy; Kenneth W. Lyles | Zendy; Steven Boonen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams

Author(s) -

Ian R. Reid,

Dennis M. Black,

Richard Eastell,

Christina BucciRechtweg,

Grace L. Su,

Trisha F. Hue,

Peter Mesenbrink,

Kenneth W. Lyles,

Steven Boonen

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2868

Subject(s) - zoledronic acid , reduction (mathematics) , medicine , mathematics , geometry

Annual infusions of zoledronic acid 5 mg over 3 years have been shown to reduce fracture incidence. There is now evidence that the effects of a single dose of zoledronic acid on bone mineral density and bone turnover last for much more than a year. Whether this is associated with sustained fracture prevention is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research